What recent price moves tell you about Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals (ALNY) has drawn investor attention after a period of mixed share performance, with the stock down over the past month and past 3 months but slightly higher over the past year.

At a share price of US$297.45, Alnylam’s short term share price return has been weak, with the stock down year to date. Longer term total shareholder returns over 3 and 5 years have been positive, hinting at shifting views on its growth and risk profile.

If you are weighing Alnylam against other opportunities in the sector, this can be a good moment to see how specialist healthcare AI stocks are trading through our 34 healthcare AI stocks

So with Alnylam trading at US$297.45, a value score of 2 and a market cap around US$40.1b, are you looking at an underappreciated RNAi leader, or has the market already priced in its future growth potential?

Most Popular Narrative: 40% Undervalued

With Alnylam last closing at $297.45 against a narrative fair value of about $491.92, the most followed storyline sees a sizeable gap between price and projected potential, built on ambitious growth and margin assumptions.

The rapid and robust uptake of AMVUTTRA for ATTR-CM in its first full quarter post-approval, combined with near-universal first-line payer access and minimal patient out-of-pocket costs, indicates a much larger addressable market for Alnylam's RNAi therapies as diagnostics and disease awareness improve, supporting sustained double-digit revenue growth.

Curious what kind of revenue curve and profit margin uplift would need to hold for that fair value to stack up? The narrative leans on faster top line expansion, widening profitability, and a richer future earnings multiple than the broader US Biotechs industry. Want to see exactly how those moving parts are combined into that higher valuation story?

Result: Fair Value of $491.92 (UNDERVALUED)

However, this story could change fast if AMVUTTRA pricing or reimbursement comes under pressure, or if heavy R&D and SG&A spending outpaces future revenue gains.

Another Way To Look At The Valuation

On simple P/E terms, Alnylam trades at 73.8x, which is much richer than the US Biotechs industry at 16.1x, peers at 30.1x, and even its own fair ratio of 29.7x. That gap points to meaningful valuation risk if sentiment or growth expectations cool. How comfortable are you paying that kind of premium?

Next Steps

With such mixed signals across price, valuation and growth narratives, now is the moment to review the underlying data yourself and consider acting before sentiment shifts. To help you weigh both the upside case and the concerns in one place, check out the 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If you stop with just one stock, you risk missing other compelling setups that could fit your goals even better, so widen your search before you commit.

• Target potential bargains by scanning companies that appear mispriced on quality and fundamentals through the 49 high quality undervalued stocks.
• Strengthen your core holdings by focusing on companies with healthier finances using the solid balance sheet and fundamentals stocks screener (46 results).
• Get ahead of the crowd by filtering for future standouts with the screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.